Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 6/20 | 0.70 |
| ▸ | PRKACA | P17612 | 3/20 | 0.62 |
| ▸ | PRKACG | P22612 | 3/20 | 0.62 |
| ▸ | PRKACB | P22694 | 3/20 | 0.62 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | NEK2 | P51955 | 1/20 | 0.50 |
| ▸ | NT5C2 | P49902 | 2/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | CDC7 | O00311 | 2/20 | 0.44 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4250092 | 0.70 | FFAR1 (0.52) | FFAR1AKR1B1FFAR4 | |
| SCHEMBL7347912 | 0.70 | FFAR1 (0.69) | FFAR1MAPK1AKR1B1FFAR4 | |
| SCHEMBL29381971 | 0.70 | FFAR1 (0.69) | FFAR1MAPK1AKR1B1FFAR4 | |
| SCHEMBL29780316 | 0.68 | FFAR1 (0.50) | FFAR1AKR1B1FFAR4 | |
| SCHEMBL13525204 | 0.68 | FFAR1 (0.71) | FFAR1AKR1B1FFAR4 | |
| SCHEMBL70271 | 0.67 | KEAP1 (0.74) | FFAR1MAPK1FFAR4 | |
| Hydrochloric Acid SCHEMBL10982620 | 0.66 | KEAP1 (0.71) | FFAR1MAPK1FFAR4 | |
| SCHEMBL4496035 | 0.65 | SMN1; SMN2 (0.70) | AKT2PRKACAPRKACGPRKACBCDK2 | |
| SCHEMBL24307632 | 0.65 | FFAR1 (0.73) | FFAR1FFAR4 | |
| SCHEMBL23794781 | 0.64 | GSK3B (0.58) | AKT2PRKACACDK2CDC7AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024211596-A1 | siRNA COMPOSITIONS TARGETING SCN9A | GENEDIT INC. (US) | 2024-10-10 | — | — | WO | claimed |
| WO-2024196893-A1 | CHEMICALLY MODIFIED NUCLEOTIDES | CAMFORD LABS INC. (US) | 2024-09-26 | — | — | WO | claimed |
| WO-2024196898-A1 | CHEMICALLY MODIFIED NONCODING NUCLEOTIDES | CAMFORD LABS INC. (US) | 2024-09-26 | — | — | WO | claimed |
| WO-2024211596-A1 | siRNA COMPOSITIONS TARGETING SCN9A | GENEDIT INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| WO-2024196893-A1 | CHEMICALLY MODIFIED NUCLEOTIDES | CAMFORD LABS INC. (US) | 2024-09-26 | — | — | WO | disclosed |
| WO-2024196898-A1 | CHEMICALLY MODIFIED NONCODING NUCLEOTIDES | CAMFORD LABS INC. (US) | 2024-09-26 | — | — | WO | disclosed |
| EP-3130597-B1 | OLIGONUCLEOTIDE HAVING A NON-NATURAL NUCLEOTIDE AT THE 5'-TERMINAL | KYOWA KIRIN CO LTD (JP) | 2021-11-10 | — | — | EP | disclosed |
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-07-09 | — | — | US | disclosed |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-14 | — | — | US | disclosed |
| EP-3130597-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | Kyowa Hakko Kirin Co., Ltd. (JP) | 2017-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | RNGTT, UPF1, NSUN3 | AKT2 3555/4885PRKACA 4399/4885PRKACG 4423/4885 |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | RNGTT, UPF1, NSUN3 | AKT2 3611/4885PRKACA 4404/4885PRKACG 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.